FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205653906> ?p ?o ?g. }

• W4205653906 endingPage "e361" @default.
• W4205653906 startingPage "e361" @default.
• W4205653906 abstract "OnabotulinumtoxinA treatment for spasticity is variable as treatment is individualized and dependent on numerous factors. Here, we explore real-world patterns of onabotulinumtoxinA utilization in patients with upper limb spasticity over 2 years. Multicenter, international, prospective, observational study (NCT01930786), examining adult patients with focal spasticity across multiple etiologies treated with onabotulinumtoxinA at their physician's discretion. Assessments include utilization (each treatment visit) and patient/physician satisfaction (5 ± 1 weeks post-treatment). Patients (n = 731) were on average 53.6 years of age (18.5–93.2 years), 52% female, and predominantly Caucasian (77%). Stroke was the most frequently reported etiology (56%). The most commonly treated upper limb spasticity presentation was clenched fist (52%). Across all clenched fist treatment sessions (n = 1505), percentage injected and dose (mode) injected into each muscle are as follows: flexor digitorum superficialis (86%, 50U), flexor digitorum profundus (80%, 50U), flexor pollicis longus (25%, 20U), flexor pollicis brevis (9%, 25U), other (6%, 20U). EMG was frequently used to localize muscles to treat clenched fist (> 44%). Across all treatment sessions, 93% of physicians and 86% of patients reported being satisfied/extremely satisfied that treatment helped manage spasticity, 84% of physicians and 76% of patients reported treatment benefit was sustained, and 99% of physicians and 92% of patients would definitely/probably continue treatment with onabotulinumtoxinA. Two hundred and sixty-one patients (36%) reported 831 adverse events (AEs); 23 AEs in 20 patients (3%) were considered treatment-related. Ninety-four patients (13%) reported 195 serious AEs; 3 serious AEs in 2 patients (0.3%) were considered treatment-related. No new safety signals were identified. ASPIRE provides valuable, real-world data on dosing, injection guidance, and muscle targeting over 2 years, that may help guide clinical strategies. This study captured the individualized nature of onabotulinumtoxinA utilization for spasticity, while demonstrating consistently high satisfaction. These results add to the body of evidence on the safety and effectiveness of onabotulinumtoxinA for spasticity." @default.
• W4205653906 created "2022-01-25" @default.
• W4205653906 creator A5001790897 @default.
• W4205653906 creator A5013743564 @default.
• W4205653906 creator A5017312037 @default.
• W4205653906 creator A5017772681 @default.
• W4205653906 creator A5033632360 @default.
• W4205653906 creator A5057058940 @default.
• W4205653906 creator A5072827067 @default.
• W4205653906 creator A5078551585 @default.
• W4205653906 creator A5079097918 @default.
• W4205653906 creator A5089135750 @default.
• W4205653906 date "2018-07-01" @default.
• W4205653906 modified "2023-09-27" @default.
• W4205653906 title "An examination of real-world onabotulinumtoxinA utilization for the treatment of upper limb spasticity: The Adult Spasticity International Registry (ASPIRE) study" @default.
• W4205653906 doi "https://doi.org/10.1016/j.rehab.2018.05.840" @default.
• W4205653906 hasPublicationYear "2018" @default.
• W4205653906 type Work @default.
• W4205653906 citedByCount "0" @default.
• W4205653906 crossrefType "journal-article" @default.
• W4205653906 hasAuthorship W4205653906A5001790897 @default.
• W4205653906 hasAuthorship W4205653906A5013743564 @default.
• W4205653906 hasAuthorship W4205653906A5017312037 @default.
• W4205653906 hasAuthorship W4205653906A5017772681 @default.
• W4205653906 hasAuthorship W4205653906A5033632360 @default.
• W4205653906 hasAuthorship W4205653906A5057058940 @default.
• W4205653906 hasAuthorship W4205653906A5072827067 @default.
• W4205653906 hasAuthorship W4205653906A5078551585 @default.
• W4205653906 hasAuthorship W4205653906A5079097918 @default.
• W4205653906 hasAuthorship W4205653906A5089135750 @default.
• W4205653906 hasBestOaLocation W42056539061 @default.
• W4205653906 hasConcept C126322002 @default.
• W4205653906 hasConcept C137627325 @default.
• W4205653906 hasConcept C1862650 @default.
• W4205653906 hasConcept C23131810 @default.
• W4205653906 hasConcept C2776660947 @default.
• W4205653906 hasConcept C2779012798 @default.
• W4205653906 hasConcept C2780573568 @default.
• W4205653906 hasConcept C42407357 @default.
• W4205653906 hasConcept C71924100 @default.
• W4205653906 hasConcept C99508421 @default.
• W4205653906 hasConceptScore W4205653906C126322002 @default.
• W4205653906 hasConceptScore W4205653906C137627325 @default.
• W4205653906 hasConceptScore W4205653906C1862650 @default.
• W4205653906 hasConceptScore W4205653906C23131810 @default.
• W4205653906 hasConceptScore W4205653906C2776660947 @default.
• W4205653906 hasConceptScore W4205653906C2779012798 @default.
• W4205653906 hasConceptScore W4205653906C2780573568 @default.
• W4205653906 hasConceptScore W4205653906C42407357 @default.
• W4205653906 hasConceptScore W4205653906C71924100 @default.
• W4205653906 hasConceptScore W4205653906C99508421 @default.
• W4205653906 hasLocation W42056539061 @default.
• W4205653906 hasOpenAccess W4205653906 @default.
• W4205653906 hasPrimaryLocation W42056539061 @default.
• W4205653906 hasRelatedWork W2021242201 @default.
• W4205653906 hasRelatedWork W2034205283 @default.
• W4205653906 hasRelatedWork W2042390181 @default.
• W4205653906 hasRelatedWork W2087649609 @default.
• W4205653906 hasRelatedWork W2116503399 @default.
• W4205653906 hasRelatedWork W2120414572 @default.
• W4205653906 hasRelatedWork W2140685464 @default.
• W4205653906 hasRelatedWork W2297275805 @default.
• W4205653906 hasRelatedWork W2810431431 @default.
• W4205653906 hasRelatedWork W4255752234 @default.
• W4205653906 hasVolume "61" @default.
• W4205653906 isParatext "false" @default.
• W4205653906 isRetracted "false" @default.
• W4205653906 workType "article" @default.